Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Published on Jan 1, 2020in Journal of Immunotherapy4.11
· DOI :10.1097/CJI.0000000000000300
Fausto Petrelli45
Estimated H-index: 45
Giulia Grizzi7
Estimated H-index: 7
+ 11 AuthorsMatteo Brighenti11
Estimated H-index: 11
Immune-related adverse events (irAEs) are autoimmune-toxic effects associated with immune checkpoint inhibitors (ICIs) used for the treatment of advanced solid tumors. We performed a systematic review and meta-analysis of the published literature to assess the outcome for cancer patients treated wit
📖 Papers frequently viewed together
20206.78BMC Medicine
6 Authors (Xiaoxiang Zhou, ..., Fengchun Zhang)
43 Citations
#1M. Grangeon (AMU: Aix-Marseille University)H-Index: 2
#2Pascale Tomasini (AMU: Aix-Marseille University)H-Index: 16
Last. Fabrice Barlesi (AMU: Aix-Marseille University)H-Index: 71
view all 13 authors...
Abstract Background Immune checkpoint inhibitors (ICIs) are available for first- and further lines of treatment of patients with advanced non–small-cell lung cancer (NSCLC). These treatments are associated with adverse events called immune-related adverse events (IRAEs). The incidence, diagnosis, and treatment of IRAEs are quite acknowledged; however, the link between IRAEs and the efficacy of ICIs requires further clarification. The objectives of this study were to assess the association betwee...
61 CitationsSource
Background Therapeutic chances for metastatic melanoma have consistently changed over the last years with the advent of antibodies targeting the programmed cell death protein-1 (PD-1). Onset of immune-related adverse events (irAEs) during treatment can be a source of concern, and the association with survival outcome is yet to be defined.
94 CitationsSource
#1Naoto Okada (University of Tokushima)H-Index: 11
#2Hitoshi Kawazoe (Ehime University)H-Index: 9
Last. Keisuke Ishizawa (University of Tokushima)H-Index: 24
view all 14 authors...
Abstract Purpose Nivolumab, an anti–programmed death 1 antibody, produces antitumor effects by activating host immunity, which also causes immune-related adverse events (irAEs). The aim of this study was to analyze the association between antitumor effect and irAEs induced by nivolumab in patients with melanoma. Methods Fifteen patients with melanoma who had received nivolumab at Tokushima University Hospital or Ehime University Hospital between January 2015 and December 2016 were enrolled in th...
52 CitationsSource
#1Doran KsienskiH-Index: 6
#2Elaine S. WaiH-Index: 17
Last. Mary Lesperance (UVic: University of Victoria)H-Index: 28
view all 10 authors...
Abstract Introduction The programmed death 1 antibodies (PD-1 Ab) nivolumab and pembrolizumab improve overall survival (OS) in advanced non–small-cell lung cancer (NSCLC). We evaluated the correlation between immune-related adverse events (irAE) and treatment interruption due to irAE on clinical efficacy of PD-1 Ab in advanced NSCLC. Patients and Methods Advanced NSCLC patients treated with PD-1 Ab between June 2015 to November 2017 at BC Cancer were identified. Demographic, tumor, treatment det...
40 CitationsSource
#1Charles K Lee (Stanford University)H-Index: 3
#2Shufeng Li (Stanford University)H-Index: 20
Last. Anne Lynn S. Chang (Stanford University)H-Index: 33
view all 7 authors...
Background Cutaneous adverse events are common with programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors. However, the nature of the specific cutaneous adverse event of dermatitis has not been investigated across various PD-1/PD-L1 inhibitors. Oncologic outcomes potentially associated with dermatitis are not well characterized. Objective To assess the nature of dermatitis after exposure to a PD-1/PD-L1 inhibitor and oncologic outcomes associated with dermatitis. Methods Retrosp...
57 CitationsSource
#1Daniel Y. Wang (VUMC: Vanderbilt University Medical Center)H-Index: 12
#2Joe-Elie Salem (University of Paris)H-Index: 29
Last. Douglas B. Johnson (VUMC: Vanderbilt University Medical Center)H-Index: 70
view all 27 authors...
Importance Immune checkpoint inhibitors (ICIs) are now a mainstay of cancer treatment. Although rare, fulminant and fatal toxic effects may complicate these otherwise transformative therapies; characterizing these events requires integration of global data. Objective To determine the spectrum, timing, and clinical features of fatal ICI-associated toxic effects. Design, Setting, and Participants We retrospectively queried a World Health Organization (WHO) pharmacovigilance database (Vigilyze) com...
677 CitationsSource
#1Cheng Xu (SYSU: Sun Yat-sen University)H-Index: 11
#2Yu Pei Chen (SYSU: Sun Yat-sen University)H-Index: 19
Last. Jun Ma (SYSU: Sun Yat-sen University)H-Index: 13
view all 15 authors...
Abstract Objective To provide a complete toxicity profile, toxicity spectrum, and a safety ranking of immune checkpoint inhibitor (ICI) drugs for treatment of cancer. Design Systematic review and network meta-analysis. Data sources Electronic databases (PubMed, Embase, Cochrane Library, and Web of Science) were systematically searched to include relevant studies published in English between January 2007 and February 2018. Review methods Only head-to-head phase II and III randomised controlled tr...
144 CitationsSource
#1Paul LesueurH-Index: 8
#2Alexandre EscandeH-Index: 14
Last. Radj GervaisH-Index: 37
view all 12 authors...
INTRODUCTION: Randomized prospective studies on patients with metastatic non-small-cell lung cancers (NSCLCs) showed that anti-programmed death-1 (PD-1) agents notably improved 2-year overall survival (OS) rates, compared to docetaxel. NSCLC patients now receive nivolumab and irradiation, concurrently or not. However, little is known about the safety of this combination, even though the preclinical model suggested a possible synergic effect. We analyzed NSCLC patients treated with radiotherapy a...
19 CitationsSource
#1Yukihiro ToiH-Index: 6
#2Shunichi SugawaraH-Index: 25
Last. Yoshihiro HondaH-Index: 4
view all 17 authors...
BACKGROUND: Immune-related adverse events (irAEs) are frequently observed with nivolumab monotherapy. This study aimed to evaluate whether the development of irAEs correlates with treatment response in advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: We conducted a retrospective study of patients who received nivolumab monotherapy at Sendai Kousei Hospital (n = 70). The patients were categorized into two groups based on the incidence of irAEs: those with irAEs (irAE group) or t...
106 CitationsSource
#1Motoko Tachihara (Kobe University)H-Index: 14
#2Shunichi NegoroH-Index: 29
Last. Soichiro YokotaH-Index: 26
view all 11 authors...
Background Immune checkpoint inhibitors (ICIs) have emerged as promising therapeutic agents in non-small cell lung cancer (NSCLC). However, the duration for which ICIs should be continued remains a clinical problem.
19 CitationsSource
Cited By29
#1Alessandro InnoH-Index: 16
#2Giandomenico Roviello (UniFI: University of Florence)H-Index: 21
Last. Fausto PetrelliH-Index: 45
view all 7 authors...
Abstract null null Background null The role of immune checkpoint inhibitors (ICI) rechallenge in cancer patients is not defined. When ICIs are discontinued due to treatment completion or toxicity, another course of ICIs is feasible in clinical practice, but the amount of data is still quite limited to draw definitive conclusions. Here we report the results of a meta-analysis evaluating efficacy and safety of ICI rechallenge. null null null Methods null PubMed, Embase, and Cochrane library were s...
#1Yang Ge (Capital Medical University)H-Index: 9
#2Huiyun Zhang (Capital Medical University)
Last. Jiannan Yao (Capital Medical University)H-Index: 6
view all 4 authors...
Abstract Background: As immune checkpoint inhibitors (ICIs) transition to the forefront of cancer treatment, a better understanding of immune related adverse events (IRAEs) is essential to promote safe clinical practice. Dermatologic adverse events are the most common IRAEs and can lead to drug withdrawal and decreased quality of life. This meta-analysis aimed to investigate the risk of the most prevalent dermatologic adverse events (pruritus and rash) among various ICI treatment regimens. Metho...
#1Pushpamali De Silva (Harvard University)H-Index: 12
#2Marco AielloH-Index: 39
Last. Cinzia SolinasH-Index: 17
view all 6 authors...
Immunotherapy approaches boosting spontaneous and durable antitumor immune responses through immune checkpoint blockade are revolutionizing treatment and patient outcomes in solid tumors and hematological malignancies. Among the various inhibitory molecules employed by the immune system to regulate the adaptive immune responses, cytotoxic T lymphocyte antigen-4 (CTLA-4) is the first successfully targeted immune checkpoint molecule in the clinic, giving rise to significant but selective benefit e...
7 CitationsSource
BACKGROUND The aim of this study was to assess the diagnostic performance of an autoantibody battery in patients receiving immune checkpoint inhibitors who experienced immune-related adverse events (irAEs). METHODS We retrospectively analyzed several variables potentially related to irAEs, namely, demographic, clinical, and laboratory characteristics, including an autoantibody battery (antinuclear, anti-neutrophil cytoplasmic, anti-thyroid antibodies and rheumatoid factor). RESULTS Sixty-nine pa...
#1Alvise Berti (Mayo Clinic)H-Index: 17
#2Roberto BortolottiH-Index: 7
Last. Antonello VecciaH-Index: 14
view all 10 authors...
INTRODUCTION The introduction in clinical practice of the immune checkpoint inhibitors (ICIs) radically changed the treatment algorithm of lung cancers. To characterize the toxicity of ICIs (atezolizumab, durvalumab, nivolumab, pembrolizumab) is important for personalizing treatment. PATIENTS AND METHODS We performed a systematic review and meta-analysis of phase III randomized controlled trials assessing ICIs, from inception until April 23rd, 2020. We extracted the data from the ICI arm of each...
#2Lidia DelrieuH-Index: 3
Last. Pierre HeudelH-Index: 7
view all 9 authors...
The response to immunotherapy has been little investigated in overweight and obese cancer patients. We evaluated the relationships between BMI, toxicity, and survival in patients treated by immunotherapy for metastatic cancer. We included metastatic cancer patients treated by immunotherapy between January 2017 and June 2020 at the Centre Leon Berard. In total, 272 patients were included: 64% men and 36% women, with a median age of 61.4 years. BMI ≥ 25 in 34.2% and 50% had non-small cell lung can...
#1Olga NigroH-Index: 8
#2Andrea C. FerrariH-Index: 136
Last. Maura MassiminoH-Index: 56
view all 8 authors...
Pediatric cancers are not the equivalent of adult cancers occurring at a younger age and the prospect of immunotherapy in children has not been received with the same enthusiasm as in the adult setting. Although most pediatric malignancies are considered immunologically cold, we are learning more about PD-L1 expression, tumor mutational burden, and microsatellite instability in several pediatric cancers. The side effects of immunotherapy are an important consideration. Immune checkpoint inhibito...
Background:Immune checkpoint inhibitors (ICIs) improved cancer therapy by inducing a higher immune system activity. This effect can cause rheumatic immune-related adverse events (rh-irAEs), which h...
1 CitationsSource
#1Yong Fan (PKU: Peking University)H-Index: 5
#2Wenhui Xie (PKU: Peking University)H-Index: 5
Last. Zhuoli Zhang (PKU: Peking University)H-Index: 30
view all 8 authors...
Objectives: Immune checkpoint inhibitors (ICIs) have brought impressive benefits to cancer patients, however often with immune-related adverse events (irAEs). We aimed to investigate the association of irAEs with efficacy and overall survival in cancer patients treated by ICIs, and further quantify the association by stratifying subgroups. Methods: PubMed, EMBASE and Cochrane library from database inception to 29 August 2019 were systematically searched. Articles reporting association of objecti...
3 CitationsSource